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Prostate cancer is the second commonest cancer among men in the developed 
countries. The incidence has been in a steep rise since 1980s, partly due to better 
diagnostic methods, for instance the discovery of tumor indicating markers such 
as PSA. However, there has been no such marker to separate an indolent cancer 
from an aggressive form at the time of the diagnosis.  
Many tumor-promoting factors have been found, one of which is micro-RNA 32 
(miR-32) that has been associated with reduced apoptosis of cancer cells. Now, 
in this study, we explored whether miR-32 affects the proliferation activity of the 
prostate cancer cells, as well. 
We had four different genotypes of murine prostates: wild type, transgenic miR-
32, transgenic hiMyc and the combination of transgenic miR-32 and hiMyc. The 
prostate sample slides were HE stained and IHC stained. In IHC staining, anti-
Ki-67 antibody was used to indicate proliferation activity and the results were an-
alyzed by counting the positive and negative cells. As a result, we discovered that 
there was no statistically significant difference between miR-32 positive and neg-
ative sample groups. Nevertheless, this may be caused by our small sample 
count (18 pc) as a recent research has indicated the proliferation increasing effect 
of miR-32.  
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Eturauhassyöpä on miesten toiseksi yleisin syöpä kehittyneissä maissa. Eturauhassyövän 
ilmaantuvuus on ollut jyrkässä kasvussa 1980-luvulta lähtien osin parantuneen diagnos-
tisten menetelmien ja merkkiaineiden, kuten PSA:n, löytämisen ansiosta. Kuitenkaan yk-
sikään keino ei ole kyennyt erottelemaan, mikä löydetty syöpä on latentti eikä aiheuta 
ongelmia miehen loppuelämän aikana ja mikä on aggressiivinen nopeasti kasvava ja le-
viävä.  
Monia merkkiaineita on löydetty ja tutkittu niiden roolia eturauhassyövän kehittymisessä, 
etenemisessä sekä eri hoitokeinojen vaikuttavuudessa. Yksi näistä on mikro-RNA 32 
(miR-32), joka on lyhyt proteiinia koodaamaton nukleotidijuoste. miR-32 on yhdistetty 
muun muassa syöpäsolujen vähentyneeseen apoptoosiin.  
Tässä työssä on selvitetty, onko miR-32:lla vaikutusta syöpäsolujen proliferaatioaktiivi-
suuteen in vivo -hiirimallissa. Työssä käytettiin genotyypiltään neljänlaisia hiirten eturau-
hasia: villi tyyppi, transgeeninen miR-32, transgeeninen hiMyc sekä transgeeninen miR-
32 ja hiMyc yhdessä. Eturauhasleikkeille tehtiin HE-värjäyksiä, ja näistä saatujen tulos-
ten perusteella valittiin leikkeet IHC-värjäykseen. IHC-värjäyksessä käytettiin anti-Ki-
67-vasta-ainetta osoittamaan jakautumisaktiiviset solut ja vastavärinä käytettiin hema-
toksyliiniä.  
IHC-värjäyksen tuloksista laskettiin solumäärät, ja analyysin lopputuloksena saatiin, ettei 
miR-32 vaikuttanut solujen jakautumisaktiivisuuteen tilastollisesti merkitsevästi. Tässä 
näytesarjassa kuitenkin eturauhasnäytteiden alhainen määrä (18 kpl) saattoi vaikuttaa, ett-
eivät mahdolliset erot tulleet esille. Hiljattain julkaistut tulokset miR-32-transgeenisillä 
hiirillä ovat osoittaneet, että miR-32 tosiaankin lisää eturauhasen rauhasepiteelin prolife-
raatioaktiivisuutta osoittaen olettamani liian pienen näytemäärän vaikutuksen syyksi ti-
lastollisesti merkitsemättömille tuloksillemme.  
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1. INTRODUCTION 
Prostate is the largest accessory sex gland and its diseases are a great cause of morbidity. 
Prostate cancer is one of the commonest health issues concerning prostate in addition to 
benign prostate hyperplasia and inflammation (Finnish Cancer Registry 2017, Kumar, 
Abbas & Aster 2015). Over 4,500 new cases are diagnosed in Finland every year so it 
affects many men (Finnish Cancer Registry 2017). However, its portion of the general 
mortality is relatively low compared to morbidity due to the old age of affected men and 
the diversity of the cancer (Finnish Cancer Registry 2017). Prostate cancer includes the 
whole spectrum from indolent, non-treatment-requiring cancer to aggressive metastatic 
form (Barbieri et al. 2013).  
The risk factors of prostate cancer are not well known (Cassidy et al. 2006). Age is con-
sidered as the most important one and also hereditary factors have been considered. How-
ever, only about 5-10% of PCa cases have been connected to certain genetic mutations, 
for instance BRCA1 and 2 (Cassidy et al. 2006).  
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2. BACKGROUND 
Prostate is a tubuloalveolar accessory sex gland of the male reproductive system (Ross, 
Pawlina 2016). It has an important role in reproduction, but it is also the second common-
est place for a cancer in men (Damber, Aus 2008).  
2.1 Prostate 
Prostate is located around the urethra under the urinary bladder (Ross, Pawlina 2016). 
Pubic symphysis is in front of the prostate and the posterior surface of the prostate is in 
contact with rectum (Drake et al. 2015). That is why the size of prostate can be palpated 
during rectal examination (Drake et al. 2015). The size of prostate can vary between men 
in correlation with their body size and age (Fowke et al. 2006). Usually older men have 
larger prostates than younger. In addition, the body mass index (BMI) associates with the 
size of prostate: the higher BMI the larger prostate (Fowke et al. 2006). The approximate 
weight of an adult prostate is 20 g ( Joensuu et al. 2013, Kumar, Abbas & Aster 2015).  
2.1.1 Structure 
Human prostate 
Prostate contains 30 to 40 individual glands which all have their own ducts (Drake et al. 
2015). These ducts empty the contents of the glands into the prostatic sinuses which are 
enlargements on the posterior surface of the urethra (Drake et al. 2015). The glands are 
composed of a lumen which is surrounded by a bilayer of cells (Kumar, Abbas & Aster 
2015). The basal layer is formed by low cuboidal cells and the second layer consisting of 
columnar cells is on top of the cuboidal cell layer (Kumar, Abbas & Aster 2015). The 
columnar cells are also called luminal cells (Shen, Abate-Shen 2010). They are polarized 
and have secretory function as they provide the secretion into the lumen of the gland. 
Luminal cells possess specific markers, for instance cytokeratins 8 and 18, which differ-
entiate them from other cells. Cuboidal cells are basal cells which can be distinguished 
from other cell types by the expression of p63 and cytoceratins 5 and 14. There is also a 
third epithelial cell type: neuroendocrine cells. They are rare and their function is not yet 
established. Furthermore, the cells can be distinguished from each other by the expression 
of androgen receptor (AR); luminal cells express AR in excessive amounts but neither 
basal nor neuroendocrine cells do. (Shen, Abate-Shen 2010) Individual glands are sepa-
rated from each other with fibromuscular stroma. (Kumar, Abbas & Aster 2015)  
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Prostate can be divided in different units anatomically and histologically. These zones are 
central zone, peripheral zone, transitional zone and periurethral zone (Drake et al. 2015, 
Kumar, Abbas & Aster 2015, Ross, Pawlina 2016). 
Central zone contains approximately a quarter of the parenchyma (Ross, Pawlina 2016). 
It is located around the ejaculatory ducts and is unlikely to have inflammation or carci-
noma. It differs histologically from other parts of prostate because the cells in this zone 
have more cytoplasm and their nuclei are larger. (Ross, Pawlina 2016)  
Peripheral zone surrounds the central zone and constitutes 70% of the parenchyma (Ross, 
Pawlina 2016). Peripheral zone is the part of prostate which can be palpated during rectal 
examination. It is also the most common site for both carcinoma and inflammation. (Ross, 
Pawlina 2016)  
Transitional zone contains only about 5% of prostate (Ross, Pawlina 2016). It surrounds 
the prostatic part of urethra. Transitional zone is the most common location for benign 
prostatic hyperplasia (BPH) because it is the site where the cells can start to divide vastly. 
Because of the location of the hyperplasia especially elderly men are more prone to have 
difficulties in urination. The glands in this zone are mucosal. (Ross, Pawlina 2016)  
Periurethral zone is also near the urethra and it is the site for late BPH (Ross, Pawlina 
2016). The hyperplasia of this zone complicates the difficulties in urination. It contains 
both mucosal and submucosal glands. Also, pathologic growth is possible mainly during 
hyperplasia. (Ross, Pawlina 2016)   
The outermost layer of prostate is an anterior fibromuscular stroma which can contract 
during ejaculation to aid the secretion to flow into the urethra (Kumar, Abbas & Aster 
2015, Ross, Pawlina 2016). The fibromuscular stroma is mostly dense irregular connec-
tive tissue and smooth muscle (Kumar, Abbas & Aster 2015, Ross, Pawlina 2016).  
Murine prostate 
Mouse has been used as a model organism in PCa for decades (Bhagavathi A. Narayanan 
et al. 2004, Foster et al. 1997, Y Sugimura, G R Cunha & A A Donjacour 1986). Also in 
this study, mouse was used as a model organism. However, murine prostate does differ 
from human prostate in some extent (Foster et al. 1997, Y Sugimura, G R Cunha & A A 
Donjacour 1986). The murine prostate is multilobular and its four lobes are more sepa-
rated from each other than human prostate zones (Scudamore 2014). The lobes are ante-
rior, lateral, dorsal and ventral lobes. The lobes are sometimes even referred as prostates 
to emphasize their separation from each other. In addition, their histological patterns are 
different, as dorsal lobe (DP) has small-diameter acini with extensive folding, on the con-
trary to large-diameter and poorly folded acini in lateral lobe (LP) and variable sized acini 
in ventral lobe (VP). Anterior lobe is also called coagulating gland (CG) and it consists 
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of a single papillary layer of epithelial cells (Scudamore 2014). Nonetheless, the basic 
functions are the same in mouse and human prostate as is their dependence on androgens 
(Y Sugimura, G R Cunha & A A Donjacour 1986).  
2.1.2 Function 
The main function of the prostate is to produce slightly alkaline fluid to semen (John E. 
Hall 2016, Ross, Pawlina 2016). The amount of protein is low in the secretion. However, 
prostate secretes many enzymes, for instance fibrinolysin, prostatic acid phosphatase 
(PAP) and prostate-specific antigen (PSA), as well as calcium, phosphate ion and citric 
acid. (John E. Hall 2016, Ross, Pawlina 2016) 
Fibrinolysin mainly has only one purpose: to keep semen liquid, whereas, PAP has more 
voluminous operating field (Ross, Pawlina 2016). PAP acts as a cell growth and metabo-
lism regulating enzyme of prostate and it can be used as a marker in PCa, especially in 
the metastatic form PAP-levels tend to rise. PSA is a serine protease which is mainly 
secreted into semen. (Ross, Pawlina 2016) PSA is a member of the tissue kallikrein fam-
ily, and human kallikrein 3 (hK3), another name for PSA, indicates this connection (John 
R. Prensner et al., Steven P. Balk, Yoo-Joung Ko & Glenn J. Bubley 2003). PSA gene is 
situated on chromosome 19q13.4 (Steven P. Balk, Yoo-Joung Ko & Glenn J. Bubley 
2003) and its transcription is induced by binding of AR (Ross, Pawlina 2016). PSA has a 
function in cleaving seminogelins to make semen more liquid (Steven P. Balk, Yoo-Joung 
Ko & Glenn J. Bubley 2003). In addition to its physiological function, PSA has a major 
therapeutic function as a tumor marker if its amount in blood is increased. PSA is also 
found in sweat glands, breast and placenta, for instance, but the function in other sites 
than prostate remain unclear. (Steven P. Balk, Yoo-Joung Ko & Glenn J. Bubley 2003)  
The secretion of prostate is important in ejaculation (John E. Hall 2016). About 30% of 
semen is secreted by prostate (Ross, Pawlina 2016). Alkalinity may be important for the 
motility and fertility of the sperm because fluid from the vas deferens is acidic to keep 
sperm inactivated (John E. Hall 2016). Sperm activation requires pH 6.0 to 6.5 in contrast 
to the pH of 3.5 to 4.0 in the fluid from vas deferens. Therefore, the secretion from pros-
tate also acts as a neutralizing factor. (John E. Hall 2016) 
With the facilitation of 5α-reductase, prostate also converts testosterone to dihydrotestos-
terone (DHT) which is 30 to 50 times more potent androgen than testosterone (Boron, 
Boulpaep 2012). 
2.1.3 Development 
The prostate develops from pelvic urethra as endodermal evaginations which became sur-
rounded by mesenchyme (Sadler, Langman 2012). The differentiation of human prostate 
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starts at the 10th week of fetal development and the secretory activity begins by the 13th 
to 15th weeks (Larsen, Schoenwolf 2009). Glandular epithelium differentiates from the 
endoderm and fibromuscular stroma in between the glands differentiates from the mes-
enchyme (Larsen, Schoenwolf 2009).  
Many signals are required for a successful development of the prostate (Shen, Abate-Shen 
2010). Most of these signals affect the interaction between mesenchyme and epithelium. 
For example, Wnt, fibroblast growth factor (FGF) and Hedgehog are crucial for organo-
genesis of prostate tissue. Wnt has been connected to ductal development as FGF is es-
sential for evagination. In addition, Hedgehog signaling pathway has been associated with 
both ductal development and evagination. Moreover, the development of the glandular 
structure is induced by the conversion of testosterone to DHT in the mesenchyme. The 
epithelium does not have ARs but the mesenchyme has and it channels effect of testos-
terone and DHT to the epithelium. (Shen, Abate-Shen 2010)   
DHT is essential for development of mesenchyme but not the epithelium (Ross, Pawlina 
2016, Shen, Abate-Shen 2010). However, it is crucial for differentiation and secretory 
function development of the epithelium. In addition, DHT maintains growth and function 
of normal prostate tissue. (Ross, Pawlina 2016, Shen, Abate-Shen 2010) DHT binds to 
AR which is in cytosol (Ross, Pawlina 2016, Isbarn et al. 2009). The DHT-AR-complex 
functions as a homodimer in the nucleus by binding to areas in DNA called hormone-
response elements (HREs). Therefore, the transcriptions of genes in question are stimu-
lated or inhibited. (Ross, Pawlina 2016, Isbarn et al. 2009) 
2.2 Prostate cancer 
Prostate cancer (PCa) is the second commonest cancer among men and the third com-
monest cancer-related cause of death in developed countries (Damber, Aus 2008). It has 
been estimated that about 161,360 new cases of PCa will be diagnosed and approximately 
26,730 men will die of it in the United States in 2017 (American Cancer Society 2017). 
PCa is mostly diagnosed with men over 65 years old and lifetime risk of PCa is approxi-
mately 14% (American Cancer Society 2017). The incidence of PCa was 4,595 and PCa 
mortality was 856 in Finland in 2014 (Finnish Cancer Registry 2017). The incidence has 
been rising steeply since late 1980s (Figure 1.).  
The commonest type of PCa is prostate adenocarcinoma (American Cancer Society 2017) 
and it is the type to which is referred in this study when discussed about PCa. Other forms 
of PCas are small-cell carcinoma, sarcomas, colloid carcinoma of the prostate, ductal ad-
enocarcinoma and mesenchymal tumors (American Cancer Society 2017, Kumar, Abbas 
& Aster 2015). Also, secondary cancer is possible, and as the most common is urothelial 
cancer which spreads to prostate (Kumar, Abbas & Aster 2015).  
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Figure 1. The number of diagnosed PCa cases annually. The steep rise in late 1980s 
was caused by discovering the PSA testing. The peak around the year 2004 was 
caused by generalized PSA screening. Data is from Finnish Cancer Registry (2017). 
2.2.1 Development of cancer 
Although PCa has been known as a disease for centuries, treatment options have been 
developed only during the past 100 years (Shen, Abate-Shen 2010). Usually, the devel-
opment of prostate cancer starts with prostatic intraepithelial neoplasia (PIN) which con-
tinues to develop into local PCa and eventually metastatic castration-resistant prostate 
cancer (CRPC) (Abdel-Khalek, El-Baz, Ibrahiem 2004, Shen, Abate-Shen 2010).  
PIN has two forms: low-grade PIN (LGPIN) and high-grade PIN (HGPIN) (Paavonen 
2017). LGPIN is clinically considered insignificant and usually is not even written in 
pathologist’s report (Paavonen 2017), but HGPIN has a significant risk to develop into 
PCa during the following 10 years (Bostwick 2000, Shen, Abate-Shen 2010). Fundamen-
tal difference between HGPIN and PCa is that the former has basal cells though their 
number is reduced but the latter does not have distinctive basal cells left (Abrahams et al. 
2003). Many samples taken from prostate represent both HGPIN as well as PCa (Abdel-
Khalek, El-Baz & Ibrahiem 2004). After development of local PCa, some cancers stay 
indolent but others progress and invade surrounding tissues and/or metastasize to other 
organs (Barbieri et al. 2013). The distinction between indolent and aggressive forms is 
not possible yet at the time of the diagnosis (John R. Prensner et al.) but some genetic 
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changes have been connected to aggressive form (Barbieri et al. 2013). For instance, ret-
inoblastoma protein is usually inactivated in CRPC but not in the local PCa (Barbieri et 
al. 2013). 
The commonest site for metastases are local lymph nodes (Shen, Abate-Shen 2010). Dis-
tant metastases usually spread through vascular system to bone. Bone tropism is espe-
cially common in PCa and the effect of cancer is generally osteoblastic changes. Other 
common sites for metastases are lung, liver and pleura. (Shen, Abate-Shen 2010)  
2.2.2 Screening, diagnosis and treatment 
PSA testing from blood has changed the diagnosing of PCa radically because PCa 
changes the structure of prostate so that PSA leaks into blood in excessive amounts (John 
R. Prensner et al., Ross, Pawlina 2016). PSA screening is not a direct indication of PCa 
because it can be elevated also in BPH, in inflammation and due to a trauma (John R. 
Prensner et al., Ross, Pawlina 2016). Furthermore, it does not differentiate whether the 
cancer is indolent or aggressive (Ross, Pawlina 2016). Both PSA-levels and the size of 
prostate is associated with the body mass index (BMI): the higher BMI, the higher PSA-
levels, and the larger prostate, therefore standard points for a normal finding is difficult 
to determine (Fowke et al. 2006). In general, total PSA 4 ng/ml has been used as a thresh-
old for normal result, although one third of PCas have PSA<4 ng/ml (Steven P. Balk, 
Yoo-Joung Ko & Glenn J. Bubley 2003). A better indication of PCa is the ratio of free 
and total PSA in blood. If this ratio is >25% when total PSA is elevated (4-10 ng/ml which 
is considered as “gray zone”), the risk of PCa is significantly lower than if ratio is <10% 
with the same total PSA value.  (Steven P. Balk, Yoo-Joung Ko & Glenn J. Bubley 2003, 
John R. Prensner et al.) Even though using PSA as diagnostic marker is complex, it is 
useful in following a response to treatment or detecting a recurrence of the cancer (Steven 
P. Balk, Yoo-Joung Ko & Glenn J. Bubley 2003).  
Biopsy is usually taken when PSAlevels are high and then the tissue sample is histopatho-
logically graded using Gleason scoring (Damber, Aus 2008, Epstein 2010, Ross, Pawlina 
2016, Shen, Abate-Shen 2010). Gleason score grades the tumors from 2 to 10, where 2 is 
most differentiated and 10 is least. The score is a sum of two commonest histological 
patterns of the sample which are graded from 1 to 5 (most and least differentiated, respec-
tively) and then summed together. (Damber, Aus 2008, Epstein 2010, Ross, Pawlina 
2016, Shen, Abate-Shen 2010) The result is presented as two numbers and their sum. The 
first number represents grade pattern which is the commonest tissue pattern in the sample 
and the second number the least differentiated component or the second commonest pat-
tern. (Sandeman et al. 2016) 
Digital rectal examination is always performed to examine the size of prostate and ultra-
sound, magnetic resonance imaging (MRI) and computed tomography (CT) are also used 
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to determine the size and possible invasion to other organs (Damber, Aus 2008, Joensuu 
et al. 2013). Bone metastases can be searched with bone scan (Bill-Axelson et al. 2015, 
Damber, Aus 2008, Joensuu et al. 2013). None of these is still able to determine whether 
PCa needs to be treated or if “watchful waiting” is the best option for maintaining the 
quality of life (Shen, Abate-Shen 2010). In localized low risk (Gleason <7) PCa, it has 
been noted that watchful waiting has the equal mortality as prostatectomy or radiation but 
quality of life (measured with urinary incontinence and sexual function, for instance) re-
main better with observation compared to radical treatment options (Barocas et al. 2017). 
Radical prostatectomy has been performed only for little over 100 years (Shen, Abate-
Shen 2010). It has been shown to reduce the PCa related deaths and risk of metastases in 
contrast to watchful waiting during the first 10 years after surgery especially patients 
younger than 65 years (Bill-Axelson et al. 2008). However, after 10 years from the sur-
gery there is no evidence of the benefit of prostatectomy in local PCa (Bill-Axelson et al. 
2008). In addition, overall mortality does not reduce significantly with radical prostatec-
tomy in contrast to watchful waiting in local PCa (Bill-Axelson et al. 2015). As a substi-
tute to radical prostatectomy, radiation can be used (Shen, Abate-Shen 2010). It can be 
performed as either external beam or implantation of radioactive pieces to the prostate 
(Shen, Abate-Shen 2010).  
There are some experimental treatments as well. One of them is high intensity focused 
ultrasound (HIFU) (Blanco Sequeiros et al. 2017). HIFU has been successfully used to 
treat leiomyomas but there is constant research on its benefits for treating diseases of 
prostate, bone and brains. There have been trials on treating PCa with HIFU but the out-
comes have been versatile. Thus, future research will show the opportunities of HIFU for 
treating PCa. (Blanco Sequeiros et al. 2017) 
The androgen deprivation therapy (ADT) has been performed from the 1940s and it can 
be combined with prostatectomy or radiation (Shen, Abate-Shen 2010). ADT is especially 
combined to the treatment if metastases or recurrence is detected (Bill-Axelson et al. 
2015). However, none of these have been showed to be enough for curing the disease and 
in the aggressive forms of PCa the cancer shall relapse eventually (John R. Prensner et 
al., Shen, Abate-Shen 2010). PCa is depended on androgens and in androgen deprivation 
therapy this dependency is utilized (Damber, Aus 2008). Physiological concentration of 
testosterone already saturates ARs so an increase in testosterone concentration to su-
praphysiologic levels does not increase the volume of prostate or the risk for PCa in 
healthy men (Isbarn et al. 2009, Morgentaler, Traish 2009). However, in PCa, and espe-
cially in CRPC, the amount of ARs has amplified through various genetic changes and 
signaling pathway stays active despite ADT (Jalava et al. 2012). Hence, the castration 
resistance usually develops within 2 years from the beginning of ADT (Damber, Aus 
2008).   
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2.2.3 MicroRNAs and cancer 
Micro-RNAs (miRNA) are small about 19-25 nucleotides long noncoding RNAs which 
are part of the posttranscriptional regulation of messenger-RNAs (mRNA) (Ambs et al. 
2008, Wang et al. 2015, Wu et al. 2013). Hence, they have an influence on apoptosis, cell 
cycle and androgen receptor pathway, for instance (Ambs et al. 2008, Wang et al. 2015, 
Wu et al. 2013). The dysfunction of miRNAs can cause problems in tissue as they regu-
late the mRNAs. In prostate, the dysfunction of miRNAs is associated with the develop-
ment pathway of PCa from PIN through local PCa to metastatic CRPC (Lo, Yang & Hsieh 
2013, Shen, Abate-Shen 2010).  
Especially in CRPC, miRNAs are expressed in a manner which differs from the normal 
prostate tissue (Jalava et al. 2012). For example, the expression of miR-573 is suppressed 
in metastatic PCa compared with the localized form (Wang et al. 2015). miRNAs can 
also act as tumor suppressors and as in the case of miR-340 it is underexpressed in PCa 
(HUANG et al. 2016). The use of miRNAs as prognostic markers has also been suggested 
(Xu et al. 2015). For instance, miR-129 is expressed in peripheral blood mononuclear 
cells and its amount is decreased in PCa. It has also tumor suppressive features, and it 
may be a target for therapeutic action in the future. (Xu et al. 2015) miRNAs do have 
tumor-promoting members, too (Jalava et al. 2012, Shen et al. 2016, Wu et al. 2013). 
One example of these is miR-32 which has been associated with decreased amount of 
apoptosis in cultured cells improving the survival of tumor cells (Jalava et al. 2012). 
Micro-RNA 32 (miR-32) is a 22 nucleotides long miRNA which is located on the long 
arm of chromosome 9, exactly at 9q31.3 (Fang, Gao 2014). miR-32 is androgen regulated 
(Jalava et al. 2012). Yet, the overexpression of miR-32 has been connected to CRPC and 
some of the samples showed moderate overexpression in PCa, too. miR-32 has been con-
nected to the underexpression of BTG2 in CRPC although the role of other mechanisms 
could not be eliminated. (Jalava et al. 2012) BTG2 is a tumor suppressor and its down-
regulation has been associated to breast cancer, PCa and laryngeal cancer, for example 
(Jalava et al. 2012, Liu et al. 2009, Rouault et al. 1996). miR-32 also has an influence on 
the phosphatase and tensin homologue (PTEN) which is known as a tumor suppressor, at 
least in colorectal carcinoma (Wu et al. 2013). miR-32 decreases the expression of PTEN, 
and, thus, the tumor may become more aggressive and invasive (Wu et al. 2013). Alt-
hough it has been shown that miR-32 suppresses apoptosis there, is no evidence whether 
it affects the proliferation activity of PCa cells (Jalava et al. 2012) 
2.3 Objective  
The aim of this research is to discover if the expression of miR-32 affects the proliferation 
activity of prostate cancer cells in vivo.  
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3. MATERIALS AND METHODS 
 
3.1 Mouse models and sample preparation 
In this study, 18 prostates from mice (age of six months) with four different genotypes 
which are wild type (WT), transgenic miR-32, transgenic hiMyc and the combination of 
transgenic miR-32 and hiMyc were used. miR-32 is the investigated miRNA and hiMyc 
is added into the genotype to provoke PCa (Ellwood-Yen et al. 2003). 
Whole prostates of mice were embedded into paraffin to make a paraffin block. Prostate 
samples were cut in a way that three slices were on a same glass and every tenth cut was 
segregated to RNA analysis. The samples were attached to glasses by heating them in 
60˚C for two hours. From the sample glasses, every third was separated into hematoxylin 
& eosin staining (HE staining) and the rest were left for immunohistochemical staining 
(IHC staining).  
3.2 Staining  
First, HE staining was executed. Second, based on tissue histology visible on the HE 
staining, there were samples selected for IHC staining. IHC staining was executed with 
anti-Ki-67 antibody. Both HE and IHC stained sample glasses were imaged with slide 
scanner microscope after staining and coverslipping.   
3.2.1 HE staining 
HE staining is the basic staining in histology (Cardiff, Miller & Munn 2014, Fischer et 
al. 2008). Hematoxylin is not strictly a basic dye but its properties are alike with basic 
dyes. Therefore, it stains nuclei purple or even black-blue. Eosin is acidic dye and thus 
stains protein components, for example collagen and elastic fibers, pink and usually cy-
toplasm is stained with different degrees of pink. (Cardiff, Miller & Munn 2014, Fischer 
et al. 2008)  
Samples were stained with KEDEE KD-RS3 Slide Stainer. The HE staining protocol is 
in Appendix 1.  
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3.2.2 Immunohistochemical staining 
Ki-67 is a proliferation marker (Questdiagnosis 2017).  There are only small amounts of 
Ki-67 in the nucleus of non-proliferating cells, but large amounts in proliferating cells 
(Questdiagnosis 2017). The large amount of Ki-67 in the nucleus of a cancer cell is asso-
ciated with poorer prognosis of the cancer (Hamilton et al. 2012). Thus, ICH staining 
with anti-Ki-67 antibody shows the Ki-67 positive and negative nuclei and consequently, 
shows the most actively proliferating cells.  
IHC staining was executed with rabbit (SP6) anti-Ki-67 antibody (Leica Biosystems) and 
counterstained with hematoxylin. Ki-67 positive nuclei appear brown whereas negative 
ones are stained blue. The staining procedure was automated with a LAB VISION Auto-
stainer 480 and the staining protocol is in detail in Appendix 2.  
3.3 Quantitative analysis 
The analysis from the proliferation activity is executed as quantitative analysis. Stained 
sample slides were whole slide imaged. Then, snapshots were taken of regions of interest 
(ROI) which were analyzed with Java-based image processing program called ImageJ. 
The Ki-67 positive nuclei were calculated from images and compared to hematoxylin 
counterstain for total nuclear count.  Based on these results, the proliferation activity 
could be estimated. 
Means of Ki-67 positivity for each different genotype sample group were calculated as 
well as standard deviation. These means were compared to each other with two-tailed t-
tests using Microsoft Office Excel 2016.  
3.4 Ethical aspects  
All animal experimentation and care procedures were carried out in accordance with 
guidelines and regulations of the national Animal Experiment Board of Finland, and were 
approved by the board of laboratory animal work of the State Provincial Offices of South 
Finland (licence number ESAVI/5147/04.10.07/2015) 
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4. RESULTS 
The Ki-67 positive and Ki-67 negative cells were counted from each ROI by eye. At least 
total of 500 cells from each ROI were counted. There are large differences in Ki-67 pos-
itivity percentages, at least between hiMyc positive and hiMyc negative samples as ex-
pected. There are also some differences in Ki-67 positivity within a sample group (Table 
1.).  In addition, samples with transgenic hiMyc outnumber the ones without as samples 
without hiMyc are used only as controls. WT samples without transgenic hiMyc expres-
sion represent normal epithelium as oncogenic hiMyc-expressing represent cancerous tu-
mors. 
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Pictures from IHC staining samples are shown in Figure 2. As predicted, hiMyc negative 
samples (Fig. 2 A, B, E and F) have fairly low number of Ki-67 positive cells on the 
contrary to hiMyc positive samples (Fig. 2 C, D, G and H) that are more Ki-67 positive 
as well as has a larger cell count in general. When looking at the pictures, it seems that 
there might be slightly more Ki-67 positive cells in miR-32 positive samples than in miR-
32 negative samples.  
Therefore, mean and standard deviation (SD) of Ki-67 positivity percentage for each sam-
ple group was calculated with Excel. The calculated values were: WT 3.9 % (SD: 1,3 %), 
transgenic miR-32 6.1 % (SD: 5.1 %), transgenic hiMyc 54.1 % (SD: 10.2 %) and the 
combination of transgenic miR-32 and transgenic hiMyc 54.2 % (SD: 7.0 %) Ki-67 pos-
itivity in IHC in the studied tissues is shown in Figure 3.  
As can be seen in Figure 3., it appears that miR-32 might have an effect to the prolifera-
tion of the cells. Therefore, there were done testing between different sample groups with 
two-sample t-tests and the results from these tests are presented in Table 2. However, as 
shown in the table, there were no statistical difference between miR-32 negative and miR-
32 positive sample groups. This indicates that miR-32 does not affect the proliferation 
activity of PCa cells. Table 2 C was used as a control to demonstrate the cancer provoking 
function of hiMyc.  
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Figure 2. IHC stainings of the samples. 40x magnification and 20x magnification are 
shown for detailed tissue structure and the general view of the tissue, respectively. 
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Figure 3. The means and SDs of Ki-67 positivity percentage of different 
sample groups are presented in a comparable form. The difference be-
tween transgenic hiMyc and without hiMyc is clear. 
Table 2. There are three separate tables from three separate t-tests. Table 
A. compares transgenic miR-32 to WT. Table B. compares transgenic 
hiMyc without miR-32 to the combination of transgenic hiMyc and trans-
genic miR-32. Table C. is used as a control to express the cancer provoking 
function of hiMyc.  
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5. DISCUSSION 
In this study, we investigated whether miR-32 affects the proliferation activity of PCa 
cells. It had already been shown to affect the apoptosis activity in vitro (Jalava et al. 
2012). Unfortunately, the results from this study did not confirm an association between 
proliferation of the cells and the presence miR-32 as the results were statistically insig-
nificant. We only had 18 mice so, perhaps, the sample number was not large enough. 
Thus, a larger number of samples might have emphasized the differences better than our 
number of samples. 
Jalava et al. showed that miR-32 could be affecting the emergence of CRPC as well as 
miR-148a (Jalava et al. 2012). They stated that miR-32 affects cells by reducing their 
apoptosis with a mechanism that remained partly unclear. At least, they found a putative 
target gene BTG2 (B-cell translocation gene 2). BTG2 suppresses cell proliferation 
through unclear mechanisms (Karve, Rosen 2012) and is downregulated by miR-32 
(Jalava et al. 2012). In addition, miR-32 was excessively overexpressed in CRPC. In our 
study, we investigated the effect of miR-32 to proliferation activity of the PCa cells. 
Jalava et al. indicated that miR-148a affects the proliferation activity but they did not 
know the same effect for miR-32 (Jalava et al. 2012). A recent research shows that ex-
pression of miR-32 increases the proliferation activity of prostate epithelium (Latonen et 
al. 2017). Therefore, the proposal that miR-32 might affect the proliferation from our 
study is true although the results were not statistically significant.  
The mouse model could be considered more reliable as it is in vivo model on the contrary 
to the in vitro model of LNCaP cells of Jalava et al. (Jalava et al. 2012). Mouse model 
can emphasize PCa better in its natural environment than cell line model because, in 
mouse, the PCa is interacting with other parts of the organism. In cell line model, the 
humoral and other signals that may have an effect to the cells are absent but, then in cell 
culture, the conditions are more controlled and the causality can be established more re-
liably than in vivo models. Additionally, LNCaP cells are human cells so their physiology 
is the same as with other human cells in comparison to mouse cells that do have at least 
a few differences to human cells. 
Nevertheless, there were many strengths in this study. First, the Ki-67 positive and nega-
tive nuclei were counted by eye which could be a weakness, too, because it is not an 
objective method as some application or software would have been. However, a software 
might not be able to deal with artefacts in the images appropriately and it could change 
the cell count whereas the counting person can assess which spot is a nucleus and which 
is not. Although, everyone has a little different how they see and evaluate colors which 
could have caused bias especially with the nuclei that are not distinctly either blue or 
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brown but somewhere in the between. Nonetheless, this can be controlled by using the 
same person to count all the pictures and after analyzing the last one, counting the first 
ROI again and checking whether the cell counts change. It was done in this study with 
the result of no change in the cell count. In addition, two people do the counting separately 
and their results are combined to decrease the possibility of a subjective error.  
Automated staining is a strength, too. A staining machine or an autostainer does the same 
staining program the same way every time. Thus, human error can be minimized espe-
cially when conducting large batches of samples with the same staining program. We 
used automated staining for both HE and IHC staining to minimize human error. In addi-
tion, as I had no previous experience in doing stainings, I was well familiarized by the 
laboratory technicians. During working I learned the procedures and, eventually, I was 
able to perform the staining by myself.  
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APPENDIX 1. HE STAINING PROTOCOL 
Table 3. HE staining program performed with KEDEE KD-RS3 Slide Stainer. 
STEP SUBSTANCE  DURATION 
STEP 01 Hexane 3 min 
STEP 02 Hexane 3 min 
STEP 03 ABS 2 min 
STEP 04 ABS 2 min 
STEP 05 94% Ethanol 2 min 
STEP 06 70% Ethanol 1 min 
STEP 07 dH2O 30 s 
STEP 08 Hematoxylin 4 min 
STEP 09 H2O 5 min 
STEP 10 dH2O 40 s 
STEP 11 Eosin 30 s 
STEP 12 H2O 1 min 
STEP 13 dH2O 30 s 
STEP 14 94% Ethanol 2 min 
STEP 15 ABS 2 min 
STEP 16 ABS 2 min 
STEP 17 ABS 2 min 
Staining was performed with KEDEE KD-RS3 Slide Stainer (Table 3.). After the stain-
ing, the slides were placed in xylene for three minutes. Then, coverslips were applied with 
Dako Coverslipper, with a DPX mounting medium. When the solutions had vaporized, 
the glasses were ready for imaging with slide scanner microscope. 
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APPENDIX 2. ANTI-KI-67 IHC STAINING PROTOCOL 
The used antibody was SP6, a rabbit anti-Ki67 antibody (Leica Biosystems).  
Sample glasses were deparaffinised by submerging in n-hexane twice for 3 minutes, then 
99.9% EtOH twice for two minutes. Then they were air dried. Using a Lab VisionTM PT 
Module, we preheated Tris-EDTA buffer containing 0.05% Tween-20 d to 65°C and the 
added the slides in. The slides were buffered to 98°C for 15min followed by cooling back 
to 65°C. We removed the slides and stored them in 1x Tris-Buffered Saline (TBS) -Tween 
solution until staining to prevent them from drying out.  
Staining was performed with a LAB VISION Autostainer 480. The program is presented 
in Table 4.  
Table 4. IHC staining program executed with a LAB VISION Autostainer 480. 
Step Solution / Reagent Time 
1 TBS-Tween Wash 
2 Blocking Agent - 3% H2O2  5 Min 
3 TBS-Tween Wash 
4 1o Antibody – SP6 1:100 dilution 
(Leica Biosystems) 
30 min 
5 TBS-Tween Wash x2 
6 2o Antibody – N-Histofine® Simple Stain MAX 
PO (Multi) 
(Nichirei Biosciences) 
30 min 
7 TBS-Tween Wash 
8 TBS-Tween Wash 
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9 Reaction Substrate - ImmPact DAB Peroxidase 
Substrate 
(Vector Laboratories) 
5 min 
10 TBS-Tween Wash x2 
11 TBS-Tween Wash 
12 Auxiliary Stain - Mayer’s Haematoxylin 2 min 
13 TBS-Tween Wash 
 
First after the staining, the samples were transferred to dH20 for 2 min. Second, they were 
dehydrated by immersing the slides in a series of 70% EtOH – 96% EtOH – 99.9% EtOH 
for 2min each. Third, the slides were submersed in xylene twice for two minutes, to pre-
pare slides for coverslipping. Coverslipping was performed with Dako Coverslipper, with 
a DPX mounting medium. After the fumes have vaporized, the slides were imaged with 
slide scanner microscope. 
 
 
